Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA? (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020
WOODCLIFF LAKE, N.J.,?Nov. 7, 2020?/PRNewswire/ --?Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus everolimus (5 mg once daily) in patients with clear-cell renal cell carcinoma (RCC) following treatment with an anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted, during an oral presentation at the International Kidney Cancer Symposium (IKCS) 2020. Results indicate that the lower starting dose (14 mg) of LENVIMA did not meet the threshold for non-inferiority compared to the FDA-approved starting dose (18 mg).
"With the influx of options for patients in the advanced RCC space, it is important that we continue to evaluate data in order to determine the most effective course of action that may help maximize therapeutic effects while managing tolerability for patients," said?Sumanta Pal, MD, Co-director of the Kidney Cancer Program and clinical professor, Department of Medical Oncology & Therapeutics at City of Hope Comprehensive Cancer Center,?Duarte, Calif., and lead investigator of the study. "The results from Study 218 show the potential benefit of LENVIMA plus everolimus in patients with advanced RCC, while providing a similar safety profile seen in previous studies."
The objective of this randomized, open-label, Phase 2 trial (NCT03173560) was to assess whether a starting dose of LENVIMA 14 mg once daily plus everolimus 5 mg once daily would provide similar efficacy with an improved safety profile compared to the FDA-approved dosage of LENVIMA 18 mg once daily plus everolimus 5 mg once daily. The primary efficacy endpoint was noninferiority of LENVIMA 14 mg versus 18 mg for objective response rate (ORR) at Week 24 (ORRWK24) (odds ratio: >0.76;?P-value: = 0.045) based on investigator assessment per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. The primary safety endpoint was superiority of the proportion of patients with intolerable Grade 2 or any = Grade 3 treatment-emergent adverse events (TEAEs) within 24 weeks after randomization in the 14 mg versus 18 mg treatment arms. Some key secondary endpoints included overall ORR, progression-free survival (PFS) overall survival (OS) and safety. The study enrolled 343 patients.
In the primary efficacy analysis (n=311 patients), ORR at week 24 for patients treated with LENVIMA at the lower starting dose (14 mg) was not non-inferior to ORR at week 24 for patients treated with the approved starting dose (18 mg) (odds ratioORRWK24: 0.88 [90%?CI: 0.59-1.32];?P-value: 0.2676).?ORR at Week 24 for patients starting with 14 mg and 18 mg was 32.1% (95% CI: 24.7-39.4) and 34.8% (95% CI: 27.3-42.3), respectively. In the primary safety analysis (n=309), the occurrence of intolerable Grade 2 or any = Grade 3 TEAEs was similar between the 14 mg and 18 mg treatment arms: 82.8% vs. 79.6% (P-value: 0.4763), respectively. The 18 mg starting dose of LENVIMA plus everolimus 5 mg demonstrated a similar safety profile as seen in a previous Phase 2 trial (Study 205). In the full safety analysis set (all patients who were randomized and received at least one dose of study drug, n=341), TEAEs led to:
In?March 2018, Eisai and Merck, known as MSD outside?the United States?and?Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA. In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer, and triple-negative breast cancer) across 19 clinical trials. About Eisai
Eisai is a leading global research and development-based pharmaceutical company headquartered in?Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our?human health care?(hhc) philosophy. We strive to realize our?hhc?philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of?hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals. For more information about Eisai, please visit?www.eisai.com?(for global),?us.eisai.com?(for U.S.) or?www.eisai.eu?(for?Europe,?Middle East,?Africa), and connect with us on Twitter (U.S.?and?global) and?LinkedIn?(for U.S.). LENVIMA??is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd. KEYTRUDA??is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,?Kenilworth, N.J., U.S.A. SOURCE Eisai Inc.
- discontinuation in 32.4% vs. 26.8% of patients who received LENVIMA 14 mg and 18 mg, respectively;
- dose interruption in 74.6% vs. 83.3% of patients who received LENVIMA 14 mg and 18 mg, respectively; and
- dose reductions in 67.6% vs. 69.6% of patients who received LENVIMA 14 mg and 18 mg, respectively.
- Median PFS was 11.1 months (95% CI: 9.0-12.9) for patients treated with 14 mg vs. 14.7 months (95% CI: 11.1-20.3) for patients treated with 18 mg; and
- Median OS was 27.0 months (95% CI: 18.3-NE) for patients treated with 14 mg vs. NE (95% CI: 23.8-NE) for patients treated with 18 mg.
- For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC)
- In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
- For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
- In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy, and are not candidates for curative surgery or radiation. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial
In?March 2018, Eisai and Merck, known as MSD outside?the United States?and?Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA. In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer, and triple-negative breast cancer) across 19 clinical trials. About Eisai
Eisai is a leading global research and development-based pharmaceutical company headquartered in?Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our?human health care?(hhc) philosophy. We strive to realize our?hhc?philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of?hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals. For more information about Eisai, please visit?www.eisai.com?(for global),?us.eisai.com?(for U.S.) or?www.eisai.eu?(for?Europe,?Middle East,?Africa), and connect with us on Twitter (U.S.?and?global) and?LinkedIn?(for U.S.). LENVIMA??is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd. KEYTRUDA??is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,?Kenilworth, N.J., U.S.A. SOURCE Eisai Inc.